**Shares of drugmaker Arcutis Biotherapeutics ARQT.O rise 12.9% to $16.91
** Co says it has agreed to temporarily pause a patent lawsuit with Israel-based Padagis regarding the latter attempting to produce a generic version of ARQT's Zoryve
** Zoryve is used to treat skin disorders including plaque psoriasis, seborrheic dermatitis and atopic dermatitis
** As part of the agreement, Padagis will keep Arcutis updated on any communication with the FDA about their generic version of Zoryve
** The patent for Zoryve is protected until at least 2037
** Including session's moves, ARQT stock up 19.4% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.